deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT03496662

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor: Bristol-Myers Squibb

Conditions Pancreatic Ductal Adenocarcinoma
Interventions BMS-813160 Biopsy Gemcitabine Nab-paclitaxel Nivolumab Peripheral blood
Updated 23 times since 2018 Last updated: Jul 28, 2025 Started: Aug 31, 2018 Primary completion: Oct 28, 2021 Completion: Jul 25, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pancreatic Ductal Adenocarcinoma and is currently completed. Bristol-Myers Squibb leads this study, which shows 23 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2018 – ~Aug 2018 · 3 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jul 2020 · 7 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jan 2024 · 12 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Aug 2025 · 6 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Feb 2025 — Aug 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 18 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jul 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Apr 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. Dec 2019 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. May 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Sep 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  17. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  18. May 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)
  • The Foundation for Barnes-Jewish Hospital
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations